

## Special Issue

# Management of Diabetes in Cardiovascular Diseases

### Message from the Guest Editor

Multiple cardiovascular (CV) risk factors, such as hypertension, dyslipidemia, obesity and inflammation, often coexist in individuals with type 2 diabetes (T2DM). Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are leading causes of morbidity and mortality for these patients. Intensive glycemic control reduces the microvascular complications of T2DM, but it does not provide a clear beneficial effect on ASCVD or HF. In recent years, several glucose-lowering drugs (GLDs) from two therapeutic families, GLP-1 receptor agonists and sodium-glucose co-transporter type 2 inhibitors, have shown a reduction in CV and renal morbidity and mortality in patients with T2DM and CV disease. A comprehensive approach to CV reduction in T2DM should include these GLDs, irrespective of the glycemic control or metformin use, and at the same level as other drugs with CV or renal protection. In summary, we have multiple tools to change the natural history of patients with T2DM and ASCVD or HF at present. We look forward to receiving your submissions to this Special Issue.

### Guest Editor

Dr. Juan José Gorgojo-Martínez

Head of Department. Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcon, Alcorcon, 28922 Madrid, Spain

### Deadline for manuscript submissions

closed (20 August 2024)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/172391](https://mdpi.com/si/172391)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).